Pfizer Inc. (NYSE:PFE) was the recipient of unusually large options trading activity on Wednesday. Stock traders acquired 2,885 call options on the company. This is an increase of 193% compared to the average volume of 986 call options.

In other news, insider Rady A. Johnson sold 4,500 shares of the company’s stock in a transaction dated Friday, March 10th. The shares were sold at an average price of $34.19, for a total value of $153,855.00. Following the sale, the insider now directly owns 54,963 shares of the company’s stock, valued at approximately $1,879,184.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Charles H. Hill sold 36,000 shares of the stock in a transaction dated Thursday, March 9th. The shares were sold at an average price of $34.07, for a total transaction of $1,226,520.00. Following the sale, the insider now directly owns 57,329 shares in the company, valued at $1,953,199.03. The disclosure for this sale can be found here. Insiders sold a total of 71,470 shares of company stock worth $2,449,150 over the last ninety days. Insiders own 0.07% of the company’s stock.

Several large investors have recently modified their holdings of the stock. Roble Belko & Company Inc increased its stake in shares of Pfizer by 0.4% in the first quarter. Roble Belko & Company Inc now owns 4,003 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 14 shares in the last quarter. D Orazio & Associates Inc. increased its stake in shares of Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 28 shares in the last quarter. Peregrine Asset Advisers Inc. increased its stake in shares of Pfizer by 0.5% in the fourth quarter. Peregrine Asset Advisers Inc. now owns 7,287 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 33 shares in the last quarter. Family Management Corp increased its stake in shares of Pfizer by 0.5% in the first quarter. Family Management Corp now owns 8,000 shares of the biopharmaceutical company’s stock valued at $274,000 after buying an additional 43 shares in the last quarter. Finally, Marcus Capital LLC increased its stake in shares of Pfizer by 0.8% in the first quarter. Marcus Capital LLC now owns 6,675 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 50 shares in the last quarter. 69.53% of the stock is currently owned by institutional investors.

Several analysts recently commented on PFE shares. Morgan Stanley reissued a “neutral” rating and set a $38.00 price objective on shares of Pfizer in a research report on Thursday, April 6th. Vetr downgraded shares of Pfizer from a “hold” rating to a “sell” rating and set a $33.45 price objective on the stock. in a research report on Thursday, March 2nd. Citigroup Inc downgraded shares of Pfizer from a “neutral” rating to a “sell” rating and cut their price objective for the company from $38.00 to $31.00 in a research report on Tuesday, May 16th. BMO Capital Markets reissued a “hold” rating and set a $33.00 price objective on shares of Pfizer in a research report on Thursday, April 27th. Finally, Sanford C. Bernstein reissued a “buy” rating and set a $35.00 price objective on shares of Pfizer in a research report on Monday, April 24th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $37.54.

Pfizer (PFE) traded up 1.603% during midday trading on Wednesday, reaching $32.645. 12,639,953 shares of the company traded hands. The stock has a market capitalization of $194.82 billion, a P/E ratio of 27.479 and a beta of 0.94. The firm has a 50-day moving average of $33.20 and a 200-day moving average of $32.98. Pfizer has a 1-year low of $29.83 and a 1-year high of $37.39.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.67 by $0.02. The company had revenue of $12.78 billion for the quarter, compared to the consensus estimate of $13.09 billion. Pfizer had a return on equity of 23.18% and a net margin of 13.50%. The firm’s revenue was down 1.7% compared to the same quarter last year. During the same period last year, the business posted $0.67 earnings per share. On average, analysts predict that Pfizer will post $2.55 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 1st. Stockholders of record on Friday, May 12th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.98%. The ex-dividend date of this dividend is Wednesday, May 10th. Pfizer’s dividend payout ratio is currently 110.35%.

TRADEMARK VIOLATION WARNING: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/05/31/pfizer-sees-unusually-large-options-volume-pfe-2.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.